NEW YORK (GenomeWeb News) – IntelligentMDx said today that it has entered into a development and licensing agreement to design, develop, and manufacture CE-marked and US Food and Drug Administration-cleared diagnostic tests for use on Qiagen's QIAsymphony RGQ platform.

IMDx did not disclose the assays, but said they will be incorporated into Qiagen's growing portfolio of molecular diagnostic assays and be distributed worldwide by Qiagen. Qiagen also retained the rights to manufacture the assays pursuant to volume considerations, IMDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.